GL701 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 3 |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00082511 (ClinicalTrials.gov) | July 2003 | 11/5/2004 | GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | Systemic Lupus Erythematosus | Drug: Prasterone (GL701) | Genelabs Technologies | NULL | Completed | 18 Years | N/A | Female | 114 | Phase 3 | United States;Mexico |
| 2 | NCT00053560 (ClinicalTrials.gov) | December 2002 | 30/1/2003 | To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids | A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | Lupus | Drug: Prasterone (GL701) | Genelabs Technologies | NULL | Active, not recruiting | 18 Years | N/A | Female | 155 | Phase 3 | United States;Mexico |
| 3 | NCT00037128 (ClinicalTrials.gov) | March 1998 | 16/5/2002 | Study of GL701 in Men With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: GL701 | Genelabs Technologies | NULL | Active, not recruiting | 18 Years | N/A | Male | 40 | Phase 3 | United States |